Browse the evidence

Early discontinuation of GLP-1RA therapy is associated with increased risks of coronary artery disease and heart failure.

Clinicians should be aware of the cardiovascular risks when patients discontinue GLP-1RA therapy early.

Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).

Clinicians should consider that patients with T2D may experience less weight loss from incretin therapies compared to those with obesity alone.

Study-level diabetes status, age, BMI, sex distribution, ethnicity, and cardiometabolic comorbidities significantly correlated with BW loss at univariate analysis.

Understanding these correlates can help tailor weight loss strategies in clinical practice.

The addition of testosterone undecanoate improved insulin sensitivity and sexual health compared to tirzepatide monotherapy.

Clinicians should consider the potential benefits of testosterone therapy on metabolic and sexual health in this patient group.

GLP-1RA therapy was associated with significant weight, glycemic, and renal benefits that were attenuated in Black adults.

It is important for practitioners to recognize that GLP-1RA therapy may have varying effectiveness across different racial groups.

On days participants reported higher-than-average incidental affect, intention, and self-monitoring, they were more likely to engage in resistance training.

Practitioners should consider the role of daily emotional states and self-monitoring in promoting resistance training among GLP-1 users.

Participants with higher levels of incidental affect, intention, and self-monitoring consistently showed a greater likelihood of participating in resistance training.

Encouraging self-monitoring and positive emotional states may enhance resistance training adherence.

On days with higher-than-average affective attitude and perceived capabilities, participants were more likely to intend to engage in resistance training.

Fostering positive attitudes and self-efficacy can be beneficial in promoting resistance training intentions.

Incretin-based therapies such as GLP-1 RA improve symptoms, exercise capacity, congestion, and reduce heart failure events in obesity-related HFpEF.

Practitioners may consider incretin-based therapies as a treatment option for improving outcomes in patients with obesity-related HFpEF.

Incretin-based therapies lead to reduced ectopic fat depositions in multiple organs and favourable cardiac remodelling.

Incretin-based therapies may be effective in reducing harmful fat deposits and improving heart structure in affected patients.

Metabolic and bariatric surgery (MBS) achieves superior comorbidity remission compared to intensive medical therapy.

MBS should be considered as a primary treatment option for patients with severe obesity and related comorbidities.

Laparoscopic Roux-en-Y gastric bypass provides superior long-term remission of dyslipidaemia, hypertension, and gastro-oesophageal reflux disease compared to laparoscopic sleeve gastrectomy.

Surgeons should consider Roux-en-Y gastric bypass for patients with specific comorbidities.

Exercise counseling was documented more frequently among patients with durable weight loss after the last GLP-1RA prescription than among those with weight regain (26.2% vs. 14.7%; P = .04).

Incorporating exercise counseling may enhance weight maintenance outcomes for patients after GLP-1RA therapy.

Preliminary dose-dependent weight reductions were observed with KN069.

KN069 may help in achieving weight loss in this demographic.

KN069 led to significant metabolic improvements including lower fasting glucose and triglycerides.

KN069 may improve metabolic health markers in this population.

GLP-1-Rezeptoragonisten, insbesondere Semaglutid, können kardiovaskuläre Ereignisse verhindern.

Semaglutid kann zur Prävention von Herz-Kreislauf-Erkrankungen bei übergewichtigen Patienten eingesetzt werden.

GLP-1 RAs demonstrate multisystemic benefits including cardiovascular risk reduction and improved renal outcomes.

Incorporating GLP-1 RAs in treatment plans may enhance overall patient health beyond weight loss.

Surgeons should recognize GLP-1 RAs as complementary tools within multidisciplinary obesity and metabolic care pathways.

Surgeons should integrate GLP-1 RAs into their treatment strategies for obesity management.

GLP-1 receptor agonist medications have the potential to promote marked weight loss.

Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.

Obesity should be framed as a chronic, multifactorial disease requiring comprehensive management strategies.

A multidisciplinary approach is essential for effective obesity management.

Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.

Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.

Current data indicate a rapid shift from single-pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes.

Practitioners should consider multimodal approaches as the future direction for treating obesity and type 2 diabetes.

64.8% of patients with obstructive sleep apnea (OSA) presenting to a sleep surgery clinic met FDA-approved criteria for GLP-1 receptor agonist (RA) use.

Practitioners should consider that a significant portion of OSA patients may be eligible for GLP-1 RA treatment.

GLP-1 RA use was associated with significantly lower rates of re-tear (RR = 0.699, p < 0.001).

Practitioners may consider GLP-1 RAs as beneficial for reducing re-tear rates in rotator cuff repair patients.